- Home
- SMMT
as 07-26-2024 4:00pm EST
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | MENLO PARK |
| Market Cap: | 3.0B | IPO Year: | N/A |
| Target Price: | $13.50 | AVG Volume (30 days): | 2.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.52 - $11.69 | Next Earning Date: | 08-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Summit Therapeutics Inc. (SMMT)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Zanganeh Mahkam | SMMT | Chief Executive Officer | Mar 26 '24 | Buy | $3.72 | 26,000 | $96,720.00 | 520,814 | SEC Form 4 |
| Dhingra Ankur | SMMT | Chief Financial Officer | Mar 26 '24 | Buy | $3.75 | 100,000 | $375,000.00 | 354,958 | SEC Form 4 |
| Dhingra Ankur | SMMT | Chief Financial Officer | Dec 13 '23 | Buy | $2.15 | 700 | $1,505.00 | 235,258 | SEC Form 4 |
| Dhingra Ankur | SMMT | Chief Financial Officer | Dec 13 '23 | Buy | $2.17 | 19,700 | $42,749.00 | 254,958 | SEC Form 4 |
| Zanganeh Mahkam | SMMT | Chief Executive Officer | Dec 11 '23 | Buy | $2.07 | 5,000 | $10,350.00 | 494,814 | SEC Form 4 |
Latest Summit Therapeutics Inc. News
SMMT Breaking Stock News: Dive into SMMT Ticker-Specific Updates for Smart Investing
Business Wire
a day ago
Summit Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Development of Ivonescimab
Business Wire
23 days ago
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
a month ago
Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors
Motley Fool
a month ago
3 Stocks That Have Soared 179% or More in 2024 and Could Go Even Higher, According to Wall Street
Zacks
a month ago
Summit (SMMT) Stock Surges 57% in the Past Month: Here's Why
MT Newswires
2 months ago
Summit Therapeutics Generates $200 Million Through Share Sale; Expand License Territories for Ivonescimab
Business Wire
2 months ago
Summit Raises $200 Million; Also Expands License Territories for Ivonescimab
Business Wire
2 months ago
Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA
Compare SMMT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SMMT Summit Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.